Journalartikel

Jahr der Veröffentlichung: 2015

Seiten: 975-981

Zeitschrift: Catheterization & Cardiovascular Interventions

Bandnummer: 86

Heftnummer: 6

ISSN: 1522-1946

eISSN: 1522-726X

DOI Link: https://doi.org/10.1002/ccd.26140

Verlag: Wiley

Abstract: 

BackgroundDiabetes is associated with aggressive atherosclerosis, leading to an increased risk of in-stent restenosis and stent thrombosis. Bioresorbable scaffolds (BRS) are a new technology for the treatment of coronary lesions that might be beneficial due to their dissolving character, especially in diabetic patients.

ObjectiveThis study was designed to evaluate feasibility and mid-term clinical outcome of the implantation of PLLA-based, everolimus-eluting BRS for the treatment of coronary lesions in a diabetic all-comers population.

MethodsAll patients of an all-comers registry with diabetes eligible for BRS implantation were included. Outcome parameters were target vessel failure (TVF), major adverse cardiac events (MACE) including target lesion revascularization (TLR), cardiac death, and myocardial infarction. Follow-up was conducted via telephone and/or office visit.

ResultsA total of 120 diabetic patients were included. Of all diabetics, 35.0% had insulin-dependent diabetes, and all other patients were treated with oral antidiabetics or dietary modification. The median age was 67 (59-72) years and 26.7% were female. Patients underwent coronary angiography due to acute coronary syndrome in 50.8%. Of 127 lesions, 60.6% were B2/C lesions according to ACC/AHA classification. The 6-month rates of TVF, TLR, and MACE were 8.9, 2.7, and 8.4%, respectively.

ConclusionThis evaluation confirms reasonable clinical outcome of bioresorbable vascular scaffold implantation in a high-risk diabetic population with predominately complex lesions during daily clinical practice. Nevertheless, long-term data are required for final evaluation. (c) 2015 Wiley Periodicals, Inc.

Harvard-Zitierstil: Wiebe, J., Gilbert, F., Doerr, O., Liebetrau, C., Wilkens, E., Bauer, T., et al. (2015) Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population, Catheterization & Cardiovascular Interventions, 86(6), pp. 975-981. https://doi.org/10.1002/ccd.26140

APA-Zitierstil: Wiebe, J., Gilbert, F., Doerr, O., Liebetrau, C., Wilkens, E., Bauer, T., Elsaesser, A., Moellmann, H., Hamm, C., & Nef, H. (2015). Implantation of everolimus-eluting bioresorbable scaffolds in a diabetic all-comers population. Catheterization & Cardiovascular Interventions. 86(6), 975-981. https://doi.org/10.1002/ccd.26140